The Objective. Presenting the financial and strategic benefits from establishment of a company for developing and manufacturing Active Pharmaceutical Ingredients (API) at RUSSIA. Business Proposition. To establish an API company at Russia.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Presenting the financial and strategic
benefits from establishment of a company
for developing and manufacturing
Active Pharmaceutical Ingredients (API)
To establish an API company at Russia.
The company will operate at the highest world quality
standards and will be a leading supplier of API for Russia
pharmaceutical companies, and will sell its products around
The initial investment will be 20 m $.
Significantly high 4 years NPV – 13 m $
Lucrative Internal rate of Return (IRR) – 37%
Potential additional income from expanding the production to final dosage forms (fdf’s)
We are a team of experts from the regulatory, r&d, marketing and operations aspects from the Pharma industry.
We have many years of experience in various positions (last as VPs of quality ,r&d and operations) in a global American based pharmaceutical company.
We are experts in production of special molecules
such as steroids and cytotoxic materials.
We want to use our many years experience in order to build and operate a high quality API production in Russia that supply first class materials to the local market and all over the world.
The Russian pharmaceutical market is one of the fastest growing in the world.
The market grow over 30% in 2008 compared to 2007 ,reaching 18.4 billion us$ . These results mean that Russia join the top ten pharmaceutical
markets in the world.
The forecast is that Russian Pharma market will reach more than 40 billion us$ in the next tenyears.
The Russian pharmaceutical market is import oriented.
80% of the drugs are manufactured abroad.
Some people define this situation as a treat on the national Russian security.
In the next 5 years this situation will change
(as a part of government program “Pharma 2020”).
Most of the drug production will move to Russian territory and will provide work for the people and taxes for the government.
The Russian government is adapting the world Pharma standards – GMP.
140 million Russian people will get high quality drugs as in Europe and USA.
This will stop the import of low quality API from
India and China and will give to a local, high quality API producer , an opportunity to supply API to a local market.
High quality Russian API company will supply materials not only to the Russian market but will function as a European company that is selling all over the world.
The company will develop and produce the following groups of materials:
4. “Usual” molecules